Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
In the latest session, Axcelis Technologies Inc (NASDAQ: ACLS) closed at $98.25 down -3.41% from its previous closing price of $101.72. In other words, the price has decreased by -$3.41 from its previous closing price. On the day, 0.62 million shares were traded. ACLS stock price reached its highest trading level at $101.61 during the session, while it also had its lowest trading level at $98.04.
Ratios:
For a deeper understanding of Axcelis Technologies Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.33 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 23.54. For the most recent quarter (mrq), Quick Ratio is recorded 2.71 and its Current Ratio is at 3.79. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.08.
On September 15, 2023, BofA Securities started tracking the stock assigning a Buy rating and target price of $225.
Craig Hallum Downgraded its Buy to Hold on August 04, 2023, whereas the target price for the stock was revised from $140 to $175.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 11 ’24 when Low Russell bought 440 shares for $112.39 per share. The transaction valued at 49,452 led to the insider holds 57,754 shares of the business.
COOGAN JAMES GORDON bought 100 shares of ACLS for $11,223 on Feb 29 ’24. The EVP AND CFO now owns 5,991 shares after completing the transaction at $112.23 per share. On Feb 23 ’24, another insider, Lawson Douglas A., who serves as the EVP, CORPORATE MKTG & STRATEGY of the company, bought 500 shares for $111.04 each. As a result, the insider paid 55,520 and bolstered with 19,648 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ACLS now has a Market Capitalization of 3203215360 and an Enterprise Value of 2775219968. As of this moment, Axcelis’s Price-to-Earnings (P/E) ratio for their current fiscal year is 13.23, and their Forward P/E ratio for the next fiscal year is 11.67. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.66. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.84 while its Price-to-Book (P/B) ratio in mrq is 3.71. Its current Enterprise Value per Revenue stands at 2.455 whereas that against EBITDA is 10.156.
Stock Price History:
Over the past 52 weeks, ACLS has reached a high of $201.00, while it has fallen to a 52-week low of $101.57. The 50-Day Moving Average of the stock is -12.43%, while the 200-Day Moving Average is calculated to be -30.84%.
Shares Statistics:
For the past three months, ACLS has traded an average of 673.39K shares per day and 477450 over the past ten days. A total of 32.69M shares are outstanding, with a floating share count of 32.12M. Insiders hold about 1.56% of the company’s shares, while institutions hold 92.47% stake in the company. Shares short for ACLS as of 1711584000 were 1974322 with a Short Ratio of 2.93, compared to 1709164800 on 1653969. Therefore, it implies a Short% of Shares Outstanding of 1974322 and a Short% of Float of 8.92.
Earnings Estimates
Currently, Apellis Pharmaceuticals, Inc. analysts are dedicated to thoroughly evaluating and rating the performance of Axcelis Technologies Inc (ACLS) in the stock market.The consensus estimate for the next quarter is $98.25, with high estimates of $54.50 and low estimates of $43.81.
Analysts are recommending an EPS of between $Healthcare and $Technology for the fiscal current year, implying an average EPS of $Technology.
